Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Geron Deal Done, AngioChem Turns To Its Own Pipeline

This article was originally published in The Pink Sheet Daily

Executive Summary

A $35 million agreement gets Geron a cancer drug that can cross the blood brain barrier - and gives AngioChem financial runway for its own pursuits.

You may also be interested in...

In Oncology Drug Boom, Can Next-Gen Cytotoxics Fit In?

The drug industry has placed a bull's eye on the field of oncology as a key therapeutic area, but not all oncology players are created equal.

Pfizer Axes Deal For Brain Cancer Vaccine, Leaves Partner Celldex In the Lurch

A brave face: Celldex execs say they are ready and able to take brain cancer vaccine CDX-110 into Phase III without a Big Pharma partner.

Slower Deal-Making Year In Oncology Leaves Numerous Appealing Targets

In terms of oncology alliances, 2009 is shaping up as slower than the previous three years, but the number of significantly priced deals has not decreased greatly

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts